ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,00%
Bitcoin
68.199,79
0,70%
Brent Oil
81,295
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Europa
  5. EU
  6. Inventiva (IVA)

  7. Inventiva (IVA) Notícias

IVA

Inventiva (IVA)

Inventiva
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:EU:IVA
DataHoraFonteTítuloCódigoCompanhia
30/05/202403:30GlobeNewswire Inc.Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024EU:IVAInventiva
30/05/202403:30GlobeNewswire Inc.Combined General Meeting of June 20, 2024 - Availability of the preparatory documentsEU:IVAInventiva
30/05/202403:30GlobeNewswire Inc.Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024EU:IVAInventiva
30/05/202403:30GlobeNewswire Inc.Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoiresEU:IVAInventiva
22/05/202417:00GlobeNewswire Inc.Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024EU:IVAInventiva
21/05/202417:00GlobeNewswire Inc.Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateEU:IVAInventiva
21/05/202417:00GlobeNewswire Inc.Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activitésEU:IVAInventiva
16/05/202417:00GlobeNewswire Inc.Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASHEU:IVAInventiva
16/05/202417:00GlobeNewswire Inc.Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASHEU:IVAInventiva
13/05/202403:30GlobeNewswire Inc.Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorEU:IVAInventiva
13/05/202403:30GlobeNewswire Inc.Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traitéEU:IVAInventiva
03/04/202417:00GlobeNewswire Inc.Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FEU:IVAInventiva
03/04/202417:00GlobeNewswire Inc.Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)EU:IVAInventiva
28/03/202404:00GlobeNewswire Inc.Inventiva announces the nomination of Andre Turenne as DirectorEU:IVAInventiva
28/03/202404:00GlobeNewswire Inc.Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateurEU:IVAInventiva
27/03/202417:00GlobeNewswire Inc.Inventiva reports its 2023 full-year resultsEU:IVAInventiva
27/03/202417:00GlobeNewswire Inc.Inventiva publie ses résultats annuels 2023EU:IVAInventiva
22/03/202417:00GlobeNewswire Inc.Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023EU:IVAInventiva
22/03/202417:00GlobeNewswire Inc.Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsEU:IVAInventiva
18/03/202417:00GlobeNewswire Inc.Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2EU:IVAInventiva
18/03/202417:00GlobeNewswire Inc.Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
13/03/202417:00GlobeNewswire Inc.Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
13/03/202417:00GlobeNewswire Inc.Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2EU:IVAInventiva
07/03/202418:00GlobeNewswire Inc.Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH  EU:IVAInventiva
07/03/202418:00GlobeNewswire Inc.Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedEU:IVAInventiva
15/02/202418:35GlobeNewswire Inc.Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3EU:IVAInventiva
15/02/202418:35GlobeNewswire Inc.Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3EU:IVAInventiva
24/01/202418:15GlobeNewswire Inc.Half-Year Review of Inventiva’s Liquidity Contract with Kepler CheuvreuxEU:IVAInventiva
24/01/202418:15GlobeNewswire Inc.Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler CheuvreuxEU:IVAInventiva
10/01/202418:00GlobeNewswire Inc.Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment BankEU:IVAInventiva
 Apresentando as notícias mais relevantes sobre:EU:IVA

Seu Histórico Recente

NASDAQ
FHCWNX
Richard Bernstein Adviso...
TG
XDND
Xtrackers IE Public
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados